MMDA-3a

MMDA-3a is a psychedelic drug and a substituted amphetamine. It is structurally related to drugs such as MDMA and MMDA, but its pharmacological effects are substantially different.

History

MMDA-3a was first synthesized by the chemist Alexander Shulgin. In his book PiHKAL, Shulgin lists the dosage of MMDA-3a as 160–240 mg, and the duration as 6–8 hours. He describes the effects of the drug as "an enhancement of music, and a peaceful elevation of mood."

Pharmacology

Like other psychedelic drugs, MMDA-3a is thought to act primarily as a 5-HT2A receptor agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Effects

The effects of MMDA-3a can vary greatly, depending on the dose and the individual's personal physiology and psychology. Some users report intense visual effects, including geometric patterns, color shifts, and distortions of spatial perception. Others describe the experience as more emotional and introspective, with a heightened sensitivity to music and other sensory stimuli, and a deep sense of peace and well-being.

Legal Status

The legal status of MMDA-3a varies by country. In the United States, it is classified as a Schedule I drug under the Controlled Substances Act, meaning it is illegal to manufacture, buy, possess, or distribute without a license from the Drug Enforcement Administration.

See Also

• Phenethylamine
• Psychedelic drug
• Substituted amphetamine

References

• Shulgin, Alexander (1991). PiHKAL: A Chemical Love Story. Transform Press. ISBN 0-9630096-0-5.

This pharmaceutical related article is a stub. You can help WikiMD by expanding it.